- Home
- SSBK vs ABOS Comparison
SSBK vs ABOS Comparison
Compare SSBK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- ABOS
- Stock Information
- Founded
- SSBK 2007
- ABOS 1996
- Country
- SSBK United States
- ABOS United States
- Employees
- SSBK N/A
- ABOS N/A
- Industry
- SSBK Commercial Banks
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- ABOS Health Care
- Exchange
- SSBK Nasdaq
- ABOS Nasdaq
- Market Cap
- SSBK 258.6M
- ABOS 152.9M
- IPO Year
- SSBK 2021
- ABOS 2021
- Fundamental
- Price
- SSBK $31.54
- ABOS $2.66
- Analyst Decision
- SSBK Buy
- ABOS Strong Buy
- Analyst Count
- SSBK 1
- ABOS 4
- Target Price
- SSBK $36.00
- ABOS $9.00
- AVG Volume (30 Days)
- SSBK 18.2K
- ABOS 185.8K
- Earning Date
- SSBK 10-29-2024
- ABOS 11-11-2024
- Dividend Yield
- SSBK 1.14%
- ABOS N/A
- EPS Growth
- SSBK N/A
- ABOS N/A
- EPS
- SSBK 3.51
- ABOS N/A
- Revenue
- SSBK $80,759,000.00
- ABOS N/A
- Revenue This Year
- SSBK N/A
- ABOS N/A
- Revenue Next Year
- SSBK $14.43
- ABOS N/A
- P/E Ratio
- SSBK $9.11
- ABOS N/A
- Revenue Growth
- SSBK N/A
- ABOS N/A
- 52 Week Low
- SSBK $22.06
- ABOS $1.81
- 52 Week High
- SSBK $34.72
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- SSBK 59.71
- ABOS 60.74
- Support Level
- SSBK $29.90
- ABOS $2.29
- Resistance Level
- SSBK $32.20
- ABOS $2.42
- Average True Range (ATR)
- SSBK 0.96
- ABOS 0.13
- MACD
- SSBK 0.29
- ABOS 0.03
- Stochastic Oscillator
- SSBK 81.87
- ABOS 100.00
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.